Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Frank Rutsch practices in Münster, Germany. Rutsch is rated as an Elite expert by MediFind in the treatment of Arterial Calcification of Infancy. He is also highly rated in 18 other conditions, according to our data. His top areas of expertise are Arterial Calcification of Infancy, Singleton-Merten Syndrome, Phenylketonuria (PKU), and Cold-Induced Sweating Syndrome.
Yvonne Nitschke practices in Muenster, Germany. Nitschke is rated as an Elite expert by MediFind in the treatment of Arterial Calcification of Infancy. She is also highly rated in 12 other conditions, according to our data. Her top areas of expertise are Arterial Calcification of Infancy, Pseudoxanthoma Elasticum, Calcinosis, and Juvenile Primary Osteoporosis.
Issam Awad is a Neurosurgery expert in Chicago, Illinois. Awad has been practicing medicine for over 43 years and is rated as a Distinguished expert by MediFind in the treatment of Arterial Calcification of Infancy. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Cerebral Cavernous Malformation, Hemangioma, Stroke, Arterial Calcification of Infancy, and Carotid Artery Surgery. Awad is currently accepting new patients.
There is no recent research available for this condition. Please check back because thousands of new papers are published every week and we strive to find and display the most recent relevant research as soon as it is available.
Summary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) recombinant fusion protein, for the treatment of ABCC6 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ABCC6 Deficie...
Summary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy, for the treatment of ENPP1 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ENPP1 Defici...